These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33197060)

  • 1. Evaluation of hepatic steatosis before liver transplantation in ex vivo by volumetric quantitative PDFF-MRI.
    Chen G; Jiang J; Wang X; Yang M; Xie Y; Guo H; Tang H; Zhou L; Hu D; Kamel IR; Chen Z; Li Z
    Magn Reson Med; 2021 May; 85(5):2805-2814. PubMed ID: 33197060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction.
    Satapathy SK; Gonzalez HC; Vanatta J; Dyer A; Angel W; Nouer SS; Kocak M; Kedia SK; Jiang Y; Clark I; Yadak N; Nezakagtoo N; Helmick R; Horton P; Campos L; Agbim U; Maliakkal B; Maluf D; Nair S; Halford HH; Eason JD
    PLoS One; 2020; 15(5):e0232006. PubMed ID: 32407331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.
    Bannas P; Kramer H; Hernando D; Agni R; Cunningham AM; Mandal R; Motosugi U; Sharma SD; Munoz del Rio A; Fernandez L; Reeder SB
    Hepatology; 2015 Nov; 62(5):1444-55. PubMed ID: 26224591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) is a viable alternative to liver biopsy for steatosis quantification in living liver donor transplantation.
    Qi Q; Weinstock AK; Chupetlovska K; Borhani AA; Jorgensen DR; Furlan A; Behari J; Molinari M; Ganesh S; Humar A; Duarte-Rojo A
    Clin Transplant; 2021 Jul; 35(7):e14339. PubMed ID: 33963602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors?
    Satkunasingham J; Nik HH; Fischer S; Menezes R; Selzner N; Cattral M; Grant D; Jhaveri K
    Liver Transpl; 2018 Apr; 24(4):470-477. PubMed ID: 29080242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Idilman IS; Keskin O; Elhan AH; Idilman R; Karcaaltincaba M
    Scand J Gastroenterol; 2014 May; 49(5):617-24. PubMed ID: 24694249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
    Han A; Zhang YN; Boehringer AS; Montes V; Andre MP; Erdman JW; Loomba R; Valasek MA; Sirlin CB; O'Brien WD
    Radiology; 2020 Apr; 295(1):106-113. PubMed ID: 32013792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.
    Wang JH; Ou HY; Yen YH; Chen CH; Lu SN
    Dig Dis Sci; 2020 May; 65(5):1512-1519. PubMed ID: 31617130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range.
    Park CC; Hooker C; Hooker JC; Bass E; Haufe W; Schlein A; Covarrubias Y; Heba E; Bydder M; Wolfson T; Gamst A; Loomba R; Schwimmer J; Hernando D; Reeder SB; Middleton M; Sirlin CB; Hamilton G
    J Magn Reson Imaging; 2019 Jan; 49(1):229-238. PubMed ID: 29707848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quantitative analysis of non-alcoholic fatty liver disease based on MRI proton density fat fraction in the coastal region of Qingdao].
    Zhu YL; Xu ZP; Yu WJ; Xin YN; Zhao ZZ; Liu SS; Lyu KR
    Zhonghua Gan Zang Bing Za Zhi; 2021 Nov; 29(11):1077-1082. PubMed ID: 34933426
    [No Abstract]   [Full Text] [Related]  

  • 13. Validation of a motion-robust 2D sequential technique for quantification of hepatic proton density fat fraction during free breathing.
    Pooler BD; Hernando D; Ruby JA; Ishii H; Shimakawa A; Reeder SB
    J Magn Reson Imaging; 2018 Dec; 48(6):1578-1585. PubMed ID: 29665193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.
    Gu J; Liu S; Du S; Zhang Q; Xiao J; Dong Q; Xin Y
    Eur Radiol; 2019 Jul; 29(7):3564-3573. PubMed ID: 30899974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.
    Idilman IS; Aniktar H; Idilman R; Kabacam G; Savas B; Elhan A; Celik A; Bahar K; Karcaaltincaba M
    Radiology; 2013 Jun; 267(3):767-75. PubMed ID: 23382293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Liver Steatosis With a Novel Ultrasound-Based Technique: A Pilot Study Using MRI-Derived Proton Density Fat Fraction as the Gold Standard.
    Ferraioli G; Maiocchi L; Raciti MV; Tinelli C; De Silvestri A; Nichetti M; De Cata P; Rondanelli M; Chiovato L; Calliada F; Filice C
    Clin Transl Gastroenterol; 2019 Oct; 10(10):e00081. PubMed ID: 31609745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes.
    Vu KN; Gilbert G; Chalut M; Chagnon M; Chartrand G; Tang A
    J Magn Reson Imaging; 2016 May; 43(5):1090-9. PubMed ID: 26536609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of hepatic steatosis using controlled attenuation parameter and MRI-derived proton density fat fraction in living donor liver transplantation.
    Zhuang RH; Weinstock AK; Ganesh S; Behari J; Malik SM; Bataller R; Furlan A; Hughes CB; Humar A; Duarte-Rojo A
    Clin Transplant; 2022 Nov; 36(11):e14786. PubMed ID: 35993599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease.
    Wang X; Zhang X; Ma L; Li S
    Sci China Life Sci; 2018 Sep; 61(9):1107-1114. PubMed ID: 29934919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diurnal Variation of Proton Density Fat Fraction in the Liver Using Quantitative Chemical Shift Encoded MRI.
    Colgan TJ; Van Pay AJ; Sharma SD; Mao L; Reeder SB
    J Magn Reson Imaging; 2020 Feb; 51(2):407-414. PubMed ID: 31168893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.